http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2875313-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d7e2f8fb5650d7d3616661464b67771 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate | 2015-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b916b0807813ff85e74526d6f19366e5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a35fe0031c2e37070b169a6ea524784 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b168e38b88091a08a8ef06e5c5d8ff1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d7a98ae9bdd14c39abf4b8a39da2843 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79ea9d965095f77d8006463f17e417e0 |
| publicationDate | 2021-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2875313-T3 |
| titleOfInvention | Pyrrolopyrimidine Compounds Used as TLR7 Agonist |
| abstract | A compound of formula (I) or a pharmaceutically acceptable salt thereof **(See formula)** wherein L1 is -O-; L2 is independently selected from the group consisting of -O-, -CH2 -, -S-, -NH-, -NHC(=O)-, -C(=O)-, -C(=O)NH-, -S(=O)-, -S(=O)2-, -NHS(=O)2- and -S(=O)2NH-, wherein the above groups are optionally substituted with one or more R4; R1 is selected from the group consisting of hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-C10 cyclohydrocarbyl, heterocyclohydrocarbyl, aryl, and 3-10 membered heteroaryl, wherein C1-10 alkyl, alkenyl C2-10, C2-10 alkynyl, C3-10 cyclohydrocarbyl, heterocyclohydrocarbyl, aryl and heteroaryl of the above 3-10 members are optionally substituted with one or more R4; R2 is selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, thiol, amino, COOH, -CONH2, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cyclohydrocarbyl, heterocyclohydrocarbyl, aryl, and heteroaryl 3-10 membered, wherein hydroxyl, thiol, amino, COOH, -CONH2, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cyclohydrocarbyl, heterocyclohydrocarbyl, aryl, and 3-10 membered heteroaryl above are optionally substituted with one or more R4; B is selected from the group consisting of aryl and heteroaryl; L3 is selected from the group consisting of C0-6 alkylene, imino, -O-, -S-, -S(=O)-, and -S(=O)2-, where C0-6 alkylene and imino above are optionally substituted with one or more R4; R3 is selected from the group consisting of hydrogen, amino, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cyclohydrocarbyl, heterocyclohydrocarbyl, aryl, and 3-10 membered heteroaryl, wherein amino, C1 alkyl -10, C2-10 alkenyl, C2-10 alkynyl, C3-10 cyclohydrocarbyl, heterocyclohydrocarbyl, aryl and heteroaryl of the above 3-10 members are optionally substituted with one or more R4; or R3 and L3 together with the adjacent atom in ring B form a 5-8 membered saturated or unsaturated ring, the 5-8 membered ring is optionally substituted with one or more R4; n is 0, 1, 2, 3, 4 or 5; R4 is selected from the group consisting of halogen, cyano, -R, -OR, =O, -SR, -NR2, =NR, -C(halogen)3, -CR(halogen)2, -CR2(halogen), -OCN, -SCN, -N=C=O, -NCS, -NO, -NO2, -NRC(=O)R, -NRC(=O)OR, -NRC(=O)NRR, -C(= O)NRR, -C(=O)OR, -OC(=O)NRR, -OC(=O)OR, -C(=O)R, -S(=O)2OR, -S(=O) 2R, -OS(=O)2OR, -S(=O)2NRR, -S(=O)R, -NRS(=O)2R, -NRS(=O)2NRR, -NRS(=O)2OR, -OP(=O)(OR)2, -P(=O)(OR)2, -C(=O)R, -C(=S)R, -C(=O)OR, -C(= S)OR, -C(=O)SR, -C(=S)SR, -C(=O)NRR, -C(=S)NRR, -C(=NR)NRR and -NRC(=NR) NRR; R is independently selected from the group consisting of H, C1-8 alkyl, C3-8 cyclohydrocarbyl, heterocyclohydrocarbyl, aryl, heteroaryl, arylalkyl, and 3-8 membered heteroarylalkyl. |
| priorityDate | 2014-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 420.